Pharming: Joenja reaches younger patients, but the shrinking core still sets the price

A headline like "Pharming wins approval of Joenja for a younger age group" reads as a small triumph for a company you may never have heard of. And in one sense it is. But the approval that actually happened was not in the United States, and it landed on top of a business that is otherwise shrinking. That gap between the good news and the company's size is the whole story here.

Joenja (leniolisib) is Pharming's treatment for APDS, an ultra-rare primary immune deficiency. The FDA first approved it in March 2023 as the first therapy for the diseasefirst approved it in March 2023 as the first therapy, but only for patients aged 12 and older. The "younger age group" in the headline — children aged 4 to 11 — is the natural next population, and getting to them matters because APDS is usually diagnosed in childhood and the most severe disease often shows up in the youngest patients.

The recent win came from Japan. In June 2026, Pharming announced Japanese approval of Joenja for patients aged 4 and older — the first approval anywhere covering that younger band — and in August it commercially launched there, the first time children aged 4 to 11 can obtain the drug anywhere in the worldfirst commercial availability of Joenja for children aged 4 to 11. For a shareholder, that is the growth asset doing exactly what it needs to do.

Why the age range is the growth engine

Pharming is effectively a two-product company in transition. RUCONEST treats hereditary angioedema, a different rare disease, and it still dominates the income statement. Joenja is the future, but it is still a minority of sales.

Look at the first quarter of 2026: total revenue was $72.4 million, down 8% from a year earliertotal revenues were US$72.4 million, an 8% decrease. RUCONEST accounted for $58.4 million of that, itself down 15% as Pharming drew down inventories and walked away from non-U.S. markets. Joenja contributed just $14.1 million — but that was up 34% year over year, the fastest-growing line in the business. In the second quarter, total revenue fell 3% to $90.2 million, with RUCONEST at $72.3 millionQ2 2026 revenue of $90.2M, down 3% YoY, still roughly 80% of sales and sliding, while Joenja kept climbing. The math is blunt: Pharming's topline is contracting even as its one growth drug accelerates, because the growth drug is not yet big enough to offset the decline.

That directly explains the stock. Pharming trades on Nasdaq (PHAR) and is down about 38% so far in 2026 and roughly 28% over the last four months, near the bottom of its 52-week range. Management cut 2026 revenue guidance in its July update to $375–395 million, $30 million below the prior $405–425 million targetRevenue – US$375-395M, lowered by US$30M. The market has been paying for RUCONEST erosion, period.

The valuation question the selloff raises

Here is where the investor has to separate a good story from a good stock. At roughly $11 a share, Pharming carries a market capitalization of about $780 million and sells for a little over two times trailing revenue. That is not an obviously cheap multiple for a company whose top line is falling and whose forward earnings are under pressure — especially when the growth asset is an orphan drug for a disease with only a few hundred documented patientswith over 285 patients identified thus far, where the addressable pool is small no matter how high the price per course.

But the selloff has also been the point at which the growth asset stopped being priced at all. Joenja's expansion to children aged 4 to 11 roughly widens the treated population, and a US decision is now the near-term catalyst that makes the thesis falsifiable. Pharming resubmitted its pediatric application to the FDA in June after a January Complete Response Letter that stemmed from manufacturing-testing questions rather than questions about how well the drug worksquestions about analytical methods used in production batch testing. The FDA set the decision date, its PDUFA target, for October 24, 2026set a October 24, 2026 PDUFA — about a month after today. If it is approved, Joenja becomes the first US treatment for APDS in children 4 to 11.

What changes the call

That October 24 decision is the single most important near-term event for the stock because it will tell you whether the growth asset can keep doing the heavy lifting. A favorable decision supports the story that Joenja eventually becomes the majority of revenue as the legacy business fades. The Japan approval shows regulators in other markets see the same evidence, which de-risks the US read to some degree.

The strongest bear fact against the whole case is arithmetic: Joenja is roughly a fifth of revenue, and the rest is declining. Until Joenja's trajectory can outrun that decline — or the multiple resets enough to price in years of contraction — a 2x-sales valuation is not automatically cheap. The honest read is that the pediatric expansion is real, durable evidence for the one part of this company that matters, and the pending US decision gives it a clock. Buy the news behind the headline, but recognize that this stock is still, for now, a watch on a shrinking core rather than a settled conclusion.